12/2017: Four projects successfully completed in Q4


Laronidase, Ipilimumab, Natalizumab, Pembrolizumab.

 


These 4 cell line development projects were successfully finalized in Q4. Ready-to-use Research Cell Banks are available for out-licensing now!



Contact us!

UGA Biopharma GmbH
16761 Hennigsdorf, Neuendorfstraße 20a (Germany)
E-Mail:  info@ugabiopharma.com This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: +49 (0)3302 / 2024900